Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lovastatin for Inhibition in ASD and NF1
NCT03826940Completed
- Sponsor
- University of Coimbra
- Start
- Feb 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, triple-blind trial of lovastatin in Autism Spectrum Disorder (ASD) and neurofibromatosis type 1 (NF1) (2 cohorts), sponsored by University of Coimbra. Primary endpoint: Neurochemical response changes to GABAergic stimulation. Started Feb 2019; status: completed.
02
Drugs
lovastatin
03
Conditions
Autism Spectrum Disorder (ASD)neurofibromatosis type 1 (NF1)
Beyond the preview
Go deeper on NCT03826940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03826940.